by RNA | Jul 20, 2021 | Client Success, Strategic Advisory
By Jeff Williamson THE SITUATION: A medical device company was preparing to launch a novel product used in interventional cardiac surgeries — one that offered improved performance, simplified clinical workflows, and reduced procedure times. The company asked... Read More
by RNA | Jul 25, 2019 | Client Success, Strategic Advisory, Valuation Advisory
THE PROBLEM: A publicly traded clinical stage biotech company needed to understand the correct implied discount rate for a lease agreement in accordance with ASC 842 rules. THE SOLUTION: ASC 842 has specific rules relating to leases, including guidance on lease... Read More
by RNA | Jul 3, 2019 | Client Success, Strategic Advisory
THE PROBLEM: A medtech start-up with a leading CE-marked product faced a strategic resource allocation decision: invest in next-generation technology in the current low-growth market, or place bets on riskier technologies in the emerging higher growth segment? THE... Read More
